A recent study suggests that patients who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who stop conventional diet and exercise regimens.
Findings released in a prominent medical journal demonstrates that while obese individuals often shed about a fifth of their body weight while using the jabs, the weight returns at an average rate of 0.8 kg per month after stopping.
"Individuals using such drugs must be cognizant of the potential of rapid rebound weight gain when the medication concludes," stated lead investigator Dr. Susan Jebb.
Such speed of regain suggests a reversion to pre-treatment mass in about 18 months.
Comparing Therapies
The study, which reviewed 37 of trials involving thousands of participants, compared the results of GLP-1 agonists with other pills.
The team emphasize that people who lose weight through dieting usually see a slower weight regain—perhaps 100 grams monthly—after stopping.
Explaining the Rapid Regain
Nutrition scientists propose the mode of action of the jabs explains the heightened weight return.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of GLP-1 levels far above than the body's typical production might result in the system to produce less of its endogenous hormone, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement means appetite is uncontrolled, making binge eating far more likely."
An Ongoing Disease?
Health authorities advise the jabs for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
Many experts argue that, due to the likelihood of relapse, the treatment is often life-long.
This view is reinforced by drug manufacturers, who state that the results "underscore the long-term character of obesity," comparing it to managing diseases like high blood pressure.
User Accounts
People who have stopped the medication describe a intense return of cravings.
"It was like something that goes on and you're instantly extremely hungry," said a patient.
The struggle is compounded if users have not established sustainable dietary or behavioural modifications during treatment.
Significant Interest
Recent estimates show that a significant number of adults in the UK have used these injections in the last 12 months, with interest remaining high.
- Use is greater among females compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
In conclusion, researchers caution that while the jabs are powerful agents for shedding pounds, they are not a standalone cure and maintained weight loss likely depends on combined behavioural management.
